Loading…
We use analytics cookies to see which pages are useful. Nothing is set unless you say yes, and we never sell your data. See our privacy policy.
E2SMed invests in and develops clinical research programmes involving regenerative medicine and autologous cell therapies. Under Australian regulation those categories cannot be advertised as treatments to the public, and the TGA enforces the rules on stem cell and biologic claims closely. A site that read like a clinic site would have created real regulatory exposure. At the same time it had to speak confidently to the audiences that matter commercially: wholesale investors, clinical partners, hospital executives and medical technology developers. That audience expects scientific credibility and clear governance language, not patient-facing marketing. The brief in one sentence: build a site that reads as a serious investment and research platform, carries its compliance framing visibly, and gives nothing away to the wrong audience.
Four decisions shaped the build. Compliance as design, not disclaimer. Patient notices and governance language were not buried in the footer. Every page carries them as designed elements with real visual weight, so the regulatory posture is legible to any reader immediately. Investor-first voice throughout. Every heading, form and call to action was pitched at wholesale investors and partners, and the contact form routes enquiries by type. The one exception is a reserved placeholder for clinical trial information that can only be published after ethics approval. Scope handled honestly. The brief doubled, then settled again as the client refined their positioning. We absorbed the back and forth and shipped the final scope at the originally agreed price. A design system rather than a template install. A deep navy palette, serif headlines, generous whitespace and a repeating compliance-banner pattern, built in native Elementor Pro widgets so the client's own team can edit it confidently.
The site launched in three weeks, on scope and on budget. Every page carries the same site-wide notice stating that the content is general corporate, research and investment information only. No page uses treatment-promotional language, patient-acquisition calls to action, or imagery of patients, doctors or clinical procedures, and that posture was briefed and client-approved at every stage. The result is a site the investor and partner audience can take seriously, and one the client's regulatory position can stand behind.
Tell us about your site and we'll show you what we'd do, starting with a free teardown.
